• Je něco špatně v tomto záznamu ?

Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV

RE. Schmieder, C. Ott, SW. Toennes, P. Bramlage, M. Gertner, O. Dawood, P. Baumgart, B. O'Brien, I. Dasgupta, G. Nickenig, J. Ormiston, M. Saxena, ASP. Sharp, H. Sievert, J. Spinar, Z. Starek, J. Weil, U. Wenzel, A. Witkowski, MD. Lobo,

. 2018 ; 36 (3) : 680-689. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028721

OBJECTIVES: The aim of this double-blind, randomized, sham-controlled study was to verify the blood pressure (BP)-lowering efficacy of externally delivered focused ultrasound for renal denervation (RDN). BACKGROUND: Nonrandomized, first proof-of-concept study and experimental evidence suggested that noninvasive techniques of RDN emerged as an alternative approach of RDN to invasive technologies. METHODS: WAVE IV, an international, randomized (1 : 1) sham-controlled, double-blind prospective clinical study, was prematurely stopped. Patients were enrolled if office BP was at least 160 mmHg and 24-h ambulatory BP was at least 135 mmHg, while taking three or more antihypertensive medications. The treatment consisted of bilateral RDN using therapeutic levels of ultrasound energy and the sham consisted of bilateral application of diagnostic levels of ultrasound energy. RESULTS: In the 81 treated patients neither changes in office BP at 12 and 24 weeks, nor changes in 24-h ambulatory BP at 24-week follow-up visit differed between the two groups significantly. Of note, no safety signal was observed. Adherence analysis disclosed full adherence in 77% at baseline and 82% at 6 months' follow-up visit. Post hoc analysis revealed that stricter criteria for stabilization of BP at baseline were associated with a numerically greater change in 24-h ambulatory BP in the RDN group than in the sham group. CONCLUSION: Our data did not prove that antihypertensive efficacy of the externally delivered focused ultrasound for RDN was greater than the sham effect. Stabilization of BP at baseline was identified as an important determinant of BP changes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028721
003      
CZ-PrNML
005      
20190823094253.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/HJH.0000000000001584 $2 doi
035    __
$a (PubMed)29035942
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schmieder, Roland E $u Department of Nephrology and Hypertension, University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg, Erlangen.
245    10
$a Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV / $c RE. Schmieder, C. Ott, SW. Toennes, P. Bramlage, M. Gertner, O. Dawood, P. Baumgart, B. O'Brien, I. Dasgupta, G. Nickenig, J. Ormiston, M. Saxena, ASP. Sharp, H. Sievert, J. Spinar, Z. Starek, J. Weil, U. Wenzel, A. Witkowski, MD. Lobo,
520    9_
$a OBJECTIVES: The aim of this double-blind, randomized, sham-controlled study was to verify the blood pressure (BP)-lowering efficacy of externally delivered focused ultrasound for renal denervation (RDN). BACKGROUND: Nonrandomized, first proof-of-concept study and experimental evidence suggested that noninvasive techniques of RDN emerged as an alternative approach of RDN to invasive technologies. METHODS: WAVE IV, an international, randomized (1 : 1) sham-controlled, double-blind prospective clinical study, was prematurely stopped. Patients were enrolled if office BP was at least 160 mmHg and 24-h ambulatory BP was at least 135 mmHg, while taking three or more antihypertensive medications. The treatment consisted of bilateral RDN using therapeutic levels of ultrasound energy and the sham consisted of bilateral application of diagnostic levels of ultrasound energy. RESULTS: In the 81 treated patients neither changes in office BP at 12 and 24 weeks, nor changes in 24-h ambulatory BP at 24-week follow-up visit differed between the two groups significantly. Of note, no safety signal was observed. Adherence analysis disclosed full adherence in 77% at baseline and 82% at 6 months' follow-up visit. Post hoc analysis revealed that stricter criteria for stabilization of BP at baseline were associated with a numerically greater change in 24-h ambulatory BP in the RDN group than in the sham group. CONCLUSION: Our data did not prove that antihypertensive efficacy of the externally delivered focused ultrasound for RDN was greater than the sham effect. Stabilization of BP at baseline was identified as an important determinant of BP changes.
650    _2
$a senioři $7 D000368
650    _2
$a antihypertenziva $x terapeutické užití $7 D000959
650    _2
$a krevní tlak $7 D001794
650    _2
$a měření krevního tlaku $7 D001795
650    12
$a denervace $7 D003714
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a předčasné ukončení klinických zkoušek $7 D057239
650    _2
$a ženské pohlaví $7 D005260
650    12
$a ablace intenzivním ultrazvukovým paprskem $7 D057086
650    _2
$a lidé $7 D006801
650    _2
$a hypertenze $x chirurgie $7 D006973
650    _2
$a ledviny $x inervace $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a neúspěšná terapie $7 D017211
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Ott, Christian $u Department of Nephrology and Hypertension, University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg, Erlangen.
700    1_
$a Toennes, Stefan W $u Institute of Legal Medicine, Forensic Toxicology Department, Goethe University, Frankfurt/Main.
700    1_
$a Bramlage, Peter $u Institute for Preventive Medicine, Mahlow, Germany.
700    1_
$a Gertner, Michael $u Kona Medical, Department of Surgery, Stanford School of Medicine, Stanford, California.
700    1_
$a Dawood, Omar $u Kona Medical, Bellevue, Washington, USA.
700    1_
$a Baumgart, Peter $u Medizinische Klinik I, Clemenshospital GmbH, Münster, Germany.
700    1_
$a O'Brien, Benjamin $u NIHR Barts Cardiovascular Biomedical Research Unit, William Harvey Research Institute. St Bartholomew's Hospital, London.
700    1_
$a Dasgupta, Indranil $u Renal Unit, Heart of England NHS Foundation Trust, Birmingham, UK.
700    1_
$a Nickenig, Georg $u Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Bonn, Bonn, Germany.
700    1_
$a Ormiston, John $u Mercy Angiography, Auckland, New Zealand.
700    1_
$a Saxena, Manish $u NIHR Barts Cardiovascular Biomedical Research Unit, William Harvey Research Institute.
700    1_
$a Sharp, Andrew S P $u Royal Exeter and Devon Hospital, Exeter, UK.
700    1_
$a Sievert, Horst $u CardioVascular Center, Sankt Katharinen Hospital, Frankfurt, Germany.
700    1_
$a Spinar, Jindrich $u Cardiology Department, University Hospital Brno. Medical Faculty, Masaryk University Brno.
700    1_
$a Starek, Zdenek $u I. International Clinical Research Center, St. Anne's University Hospital, 1st Department of Internal Medicine/Cardioangiology, Brno, Czech Republic.
700    1_
$a Weil, Joachim $u Medizinische Klinik II, Kardiologie und Angiologie, Sana Kliniken Lübeck, Lübeck.
700    1_
$a Wenzel, Ulrich $u Universitätsklinikum Hamburg-Eppendorf, III. Medizinische Klinik und Poliklinik Hamburg, Germany.
700    1_
$a Witkowski, Adam $u Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland.
700    1_
$a Lobo, Melvin D $u NIHR Barts Cardiovascular Biomedical Research Unit, William Harvey Research Institute.
773    0_
$w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 36, č. 3 (2018), s. 680-689
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29035942 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823094507 $b ABA008
999    __
$a ok $b bmc $g 1433870 $s 1067181
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 36 $c 3 $d 680-689 $e - $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace